B Shiek Ahmad1,2, S J Petty1, A Gorelik1,3, T J O'Brien1, K D Hill4, J J Christie1, P N Sambrook5, J D Wark6,7. 1. Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Level 4, Clinical Sciences Building, Parkville, Victoria, 3050, Australia. 2. Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. 3. Melbourne EpiCentre, The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia. 4. School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, 6845, Australia. 5. Department of Medicine, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, 2006, Australia. 6. Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Level 4, Clinical Sciences Building, Parkville, Victoria, 3050, Australia. jdwark@unimelb.edu.au. 7. The Royal Melbourne Hospital Bone and Mineral Service, Parkville, Victoria, 3050, Australia. jdwark@unimelb.edu.au.
Abstract
Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility. INTRODUCTION: To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use, including enzyme-inducing (EIAED) and non-enzyme-inducing (NEIAED) types, and other predictors of bone loss in a study of 48 same-sex twin/age-matched sibling pairs (40 female, 8 male) discordant for AED use. METHODS: Using dual-energy X-ray absorptiometry (DXA), areal bone mineral density (aBMD) and content (BMC) at the hip regions, forearm, lumbar spine, and whole body were measured twice, at least 2 years apart. The mean within-pair difference (MWPD), MWPD%, and mean annual rate of aBMD change were adjusted for age, weight, and height. Predictors of bone loss were evaluated. RESULTS: AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013) and whole body regions (0.7% loss vs. 0.1% BMD gain, p = 0.019), which was not found in NEIAED-discordant pairs (n = 16). AED use >20 years predicted higher aBMD loss at the forearm (p = 0.028), whole body (p = 0.010), and whole body BMC (p = 0.031). CONCLUSIONS: AED users had reduced aBMD at the hip regions. Prolonged users and EIAED users had greater aBMD loss, predicting a higher risk of bone fragility. Further prospective studies of AED effects on bone microarchitecture are needed.
Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility. INTRODUCTION: To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use, including enzyme-inducing (EIAED) and non-enzyme-inducing (NEIAED) types, and other predictors of bone loss in a study of 48 same-sex twin/age-matched sibling pairs (40 female, 8 male) discordant for AED use. METHODS: Using dual-energy X-ray absorptiometry (DXA), areal bone mineral density (aBMD) and content (BMC) at the hip regions, forearm, lumbar spine, and whole body were measured twice, at least 2 years apart. The mean within-pair difference (MWPD), MWPD%, and mean annual rate of aBMD change were adjusted for age, weight, and height. Predictors of bone loss were evaluated. RESULTS: AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013) and whole body regions (0.7% loss vs. 0.1% BMD gain, p = 0.019), which was not found in NEIAED-discordant pairs (n = 16). AED use >20 years predicted higher aBMD loss at the forearm (p = 0.028), whole body (p = 0.010), and whole body BMC (p = 0.031). CONCLUSIONS: AED users had reduced aBMD at the hip regions. Prolonged users and EIAED users had greater aBMD loss, predicting a higher risk of bone fragility. Further prospective studies of AED effects on bone microarchitecture are needed.
Entities:
Keywords:
Antiepileptic drug; Bone mineral density (BMD); Dual-energy X-ray absorptiometry (DXA); Epilepsy; Longitudinal study
Authors: Baemisla Shiek Ahmad; Keith David Hill; Terence John O'Brien; Alexandra Gorelik; Natalie Habib; John Dennis Wark Journal: Neurology Date: 2012-06-13 Impact factor: 9.910
Authors: Baemisla Shiek Ahmad; Terence John O'Brien; Alexandra Gorelik; Keith David Hill; John Dennis Wark Journal: J Clin Densitom Date: 2016-08-20 Impact factor: 2.617
Authors: Philipp Schneider; Martin Stauber; Romain Voide; Marco Stampanoni; Leah Rae Donahue; Ralph Müller Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741
Authors: Rhys D Brady; Ker Rui Wong; Dale L Robinson; Richelle Mychasiuk; Stuart J McDonald; Ryan A D'Cunha; Glenn R Yamakawa; Mujun Sun; John D Wark; Peter Vee Sin Lee; Terence J O'Brien; Pablo M Casillas-Espinosa; Sandy R Shultz Journal: Front Pharmacol Date: 2019-10-29 Impact factor: 5.810